Price T Rowe Associates Inc Altimmune, Inc. Transaction History

Price T Rowe Associates Inc

$816 Billion
Q1 2024

A detailed history of Price T Rowe Associates Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 15,238 shares of ALT stock, worth $104,989. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,238

Previous 13,417 13.57%

Holding current value

$104,989

Previous $151,000 3.31%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $14,968 - $25,148	1,821 Added 13.57%	15,238 $156,000
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $7,211 - $39,159	3,370 Added 33.54%	13,417 $151,000
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $37,440 - $53,820	-15,600 Reduced 60.83%	10,047 $27,000
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $20,172 - $34,906	5,847 Added 29.53%	25,647 $91,000
Q1 2023 May 15, 2023	SELL	$4.19 - $16.83 $67,459 - $270,963	-16,100 Reduced 44.85%	19,800 $84,000

Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $862,760 - $1.62 Million	-98,714 Reduced 73.33%	35,900 $591,000
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $1.06 Million - $2.22 Million	99,014 Added 278.13%	134,614 $1.72 Million
Q2 2022 Aug 15, 2022	SELL	$3.94 - $11.77 $13,604 - $40,641	-3,453 Reduced 8.84%	35,600 $417,000
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $4,920 - $7,881	834 Added 2.18%	39,053 $238,000
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $51,271 - $73,632	5,900 Added 18.26%	38,219 $350,000
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $2,815 - $5,614	334 Added 1.04%	32,319 $366,000
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $158,732 - $265,252	-16,115 Reduced 33.5%	31,985 $315,000
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $90,241 - $172,601	7,100 Added 17.32%	48,100 $680,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $321,440 - $583,020	41,000 New	41,000 $462,000

Others Institutions Holding ALT

# of Institutions

185

Shares Held

44.4M

Call Options Held

1.1M

Put Options Held

647K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $338M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Altimmune, Inc. Transaction History